Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
Status: | Recruiting |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 3/31/2019 |
Start Date: | September 22, 2014 |
End Date: | February 2024 |
Contact: | Amy Maurer, MA |
Email: | amy.maurer@bsci.com |
Phone: | 508-683-6647 |
REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation
The objective of this study is to evaluate the safety and effectiveness of the Lotus™ Valve
System and LOTUS Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in
symptomatic subjects with calcific, severe native aortic stenosis who are considered at
extreme or high risk for surgical valve replacement.
System and LOTUS Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in
symptomatic subjects with calcific, severe native aortic stenosis who are considered at
extreme or high risk for surgical valve replacement.
Inclusion Criteria:
1. Subject has documented calcific, severe native aortic stenosis with an initial aortic
valve area (AVA) of ≤1.0 cm2 (or AVA index of ≤0.6 cm2/m2) and a mean pressure
gradient >40 mm Hg or jet velocity >4.0 m/s, as measured by echocardiography and/or
invasive hemodynamics
2. Subject has a documented aortic annulus size of ≥18 mm and ≤29 mm based on the
center's assessment of pre-procedure diagnostic imaging (and confirmed by the Case
Review Committee [CRC]) and, for the randomized cohort, is deemed treatable with an
available size of both test and control device. For the U.S. Continued Access Study
cohort the acceptable aortic annulus size is ≥20 mm and ≤27 mm.
3. Subject has symptomatic aortic valve stenosis with New York Heart Association (NYHA)
Functional Class ≥ II
4. There is agreement by the heart team (which must include a site investigator
interventionalist and a site investigator cardiac surgeon) that subject is at high or
extreme operative risk for surgical valve replacement (see note below for definitions
of extreme and high risk, the required level of surgical assessment, and CRC
confirmation) and that TAVR is appropriate. Additionally, subject has at least one of
the following.
- Society of Thoracic Surgeons (STS) score ≥8% -OR-
- If STS <8, subject has at least one of the following conditions: Hostile chest,
porcelain aorta, severe pulmonary hypertension (>60 mmHg), prior chest radiation
therapy, coronary artery bypass graft(s) at risk with re-operation, severe lung
disease (need for supplemental oxygen, forced expiratory volume in 1 second
[FEV1] <50% of predicted, diffusing capacity of the lungs for carbon monoxide
[DLCO] <60%, or other evidence of severe pulmonary dysfunction), neuromuscular
disease that creates risk for mechanical ventilation or rehabilitation after
surgical aortic valve replacement, orthopedic disease that creates risk for
rehabilitation after surgical aortic valve replacement, Childs Class A or B liver
disease (subjects with Childs Class C disease are not eligible for inclusion in
this trial), frailty as indicated by at least one of the following: 5‑meter walk
>6 seconds, Katz Assessment of Daily Living (Katz ADL) score of 3/6 or less, body
mass index <21, wheelchair bound, unable to live independently, age ≥90 years,
other evidence that subject is at high or extreme risk for surgical valve
replacement (CRC must confirm agreement with site heart team that subject meets
high or extreme risk definition)
5. Heart team (which must include a cardiac interventionalist and an experienced cardiac
surgeon) assessment that the subject is likely to benefit from valve replacement.
6. Subject (or legal representative) understands the study requirements and the treatment
procedures, and provides written informed consent.
7. Subject, family member, and/or legal representative agree(s) and subject is capable of
returning to the study hospital for all required scheduled follow up visits.
Note: Extreme operative risk and high operative risk are defined as follows: Extreme
Operative Risk: Predicted operative mortality or serious, irreversible morbidity risk ≥50%
at 30 days; High Operative Risk: Predicted operative mortality or serious, irreversible
morbidity risk ≥15% at 30 days. Risk of operative mortality and morbidity must be assessed
via an in-person evaluation by a center cardiac surgeon and must be confirmed by the CRC
(which must include an experienced cardiac surgeon).
Exclusion Criteria:
1. Subject has a congenital unicuspid or bicuspid aortic valve.
2. Subject has had an acute myocardial infarction (MI) within 30 days prior to the index
procedure (defined as Q-wave MI or non-Q-wave MI with total creatine kinase (CK)
elevation ≥ twice normal in the presence of creatine kinase-myoglobin band (CK-MB)
elevation and/or troponin elevation).
3. Subject has had a cerebrovascular accident or transient ischemic attack within the
past 6 months prior to study enrollment.
4. Subject has end-stage renal disease or has glomerular filtration rate (GFR) <20 (based
on Cockcroft-Gault formula).
5. Subject has a pre-existing prosthetic aortic or mitral valve.
6. Subject has severe (4+) aortic, tricuspid, or mitral regurgitation.
7. Subject has a need for emergency surgery for any reason.
8. Subject has a history of endocarditis within 6 months of index procedure or evidence
of an active systemic infection or sepsis.
9. Subject has echocardiographic evidence of new intra-cardiac mass, vegetation or
intraventricular or paravalvular thrombus requiring intervention.
10. Subject has (hemoglobin) Hgb <9 g/dL, platelet count <50,000 cells/mm3 or >700,000
cells/mm3, or white blood cell count <1,000 cells/mm3.
11. Subject requires chronic anticoagulation therapy after the implant procedure and
cannot be treated with warfarin (other anticoagulants are not permitted in the first
month) for at least 1 month concomitant with either aspirin or clopidogrel.
12. Subject has had a gastrointestinal bleed requiring hospitalization or transfusion
within the past 3 months, or has other clinically significant bleeding diathesis or
coagulopathy that would preclude treatment with required antiplatelet regimen, or will
refuse transfusions.
13. Subject has known hypersensitivity to contrast agents that cannot be adequately
pre-medicated, or has known hypersensitivity to aspirin, all P2Y12 inhibitors,
heparin, nickel, tantalum, titanium, or polyurethanes.
14. Subject has a life expectancy of less than 12 months due to non-cardiac, comorbid
conditions based on the assessment of the investigator at the time of enrollment.
15. Subject has hypertrophic obstructive cardiomyopathy.
16. Subject has any therapeutic invasive cardiac or vascular procedure within 30 days
prior to the index procedure (except for balloon aortic valvuloplasty or pacemaker
implantation, which are allowed).
17. Subject has untreated coronary artery disease, which in the opinion of the treating
physician is clinically significant and requires revascularization.
18. Subject has severe left ventricular dysfunction with ejection fraction <20%.
19. Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic
support or mechanical support devices.
20. Subject has severe vascular disease that would preclude safe access (e.g., aneurysm
with thrombus that cannot be crossed safely, marked tortuosity, significant narrowing
of the abdominal aorta, severe unfolding of the thoracic aorta, or symptomatic carotid
or vertebral disease).
21. Subject has thick (>5 mm) protruding or ulcerated atheroma in the aortic arch
22. Subject has arterial access that is not acceptable for the test and control device
delivery systems as defined in the device Instructions For Use.
23. Subject has current problems with substance abuse (e.g., alcohol, etc.).
24. Subject is participating in another investigational drug or device study that has not
reached its primary endpoint.
25. Subject has untreated conduction system disorder (e.g., Type II second degree
atrioventricular block) that in the opinion of the treating physician is clinically
significant and requires a pacemaker implantation. Enrollment is permissible after
permanent pacemaker implantation.
26. Subject has severe incapacitating dementia.
We found this trial at
52
sites
2049 E 100th St
Cleveland, Ohio 44106
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Samir Kapadia, MD
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Donald Cutlip, MD
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
3 Gates Circle
Buffalo, New York 14209
Buffalo, New York 14209
716-887-4219
Principal Investigator: Vijay Iyer, MD
Click here to add this to my saved trials
7777 Forest Ln # C840
Dallas, Texas 75230
Dallas, Texas 75230
(972) 566-7000
Principal Investigator: Todd Dewey, MD
Medical City Dallas Hospital If you have concerns for your health, that of a family...
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
Falls Church, Virginia 22042
(703) 776-4001
Principal Investigator: Shahram Yazdani, MD
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Raj Makkar, MD
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Bruce Rutkin, MD
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
8900 North Kendall Drive
Miami, Florida 33176
Miami, Florida 33176
Principal Investigator: Ramon Quesada, MD
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-4000
Principal Investigator: Howard Herrmann, MD
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
Click here to add this to my saved trials
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
Atlanta, Georgia 30322
(404) 712-2000
Principal Investigator: Robert Guyton, MD
Emory University Hospital As the largest health care system in Georgia and the only health...
Click here to add this to my saved trials
1968 Peachtree Rd NW
Atlanta, Georgia 30309
Atlanta, Georgia 30309
(404) 605-5000
Principal Investigator: Vivek Rajagopal, MD
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
Click here to add this to my saved trials
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Dean Kereiakas, MD
Click here to add this to my saved trials
Clearwater, Florida 33756
Principal Investigator: Joshua Rovin, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbus, Ohio 43215
Principal Investigator: Steven Yakubov, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Kevin Harrison, MD
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
2650 Ridge Ave.
Evanston, Illinois 60201
Evanston, Illinois 60201
847.570.2000
Principal Investigator: Ted Feldman, MD
Evanston Hospital Evanston Hospital, opened in 1891, is the nucleus of the NorthShore University HealthSystem....
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Neal Kleiman, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Scripps Clinic Scripps Clinic in Torrey Pines has been providing exceptional medical care to people...
Click here to add this to my saved trials
1400 NW 12th Ave
Miami, Florida 33136
Miami, Florida 33136
(305) 689-5511
Principal Investigator: Mauricio Cohen, MD
University of Miami Hospital The University of Miami changed the face of modern health care...
Click here to add this to my saved trials
2900 W Oklahoma Ave
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53215
414-649-6000
Principal Investigator: Tanvir Bajwa, MD
Aurora St. Luke's Medical Center At Aurora St. Luke's Medical Center, you'll find remarkable treatment...
Click here to add this to my saved trials
Winthrop University Hospital Founded in 1896 by a group of local physicians and concerned citizens,...
Click here to add this to my saved trials
Minneapolis, Minnesota 55407
Principal Investigator: Wesley Pedersen, MD
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Gregory Helmer, MD
Click here to add this to my saved trials
100 Madison Ave
Morristown, New Jersey 7960
Morristown, New Jersey 7960
(973) 971-5000
Principal Investigator: Barry Cohen, MD
Morristown Memorial Hospital Atlantic Health System – comprised of Morristown Medical Center, Overlook Medical Center,...
Click here to add this to my saved trials
630 W 168th St
New York, New York
New York, New York
212-305-2862
Principal Investigator: Tamim Nazif, MD
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: John Giacomini, MD
Click here to add this to my saved trials
Petoskey, Michigan 49770
Principal Investigator: Louis Cannon, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Pittsburgh, Pennsylvania 15213
Principal Investigator: Thomas Gleason, MD
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
Click here to add this to my saved trials
9205 SW Barnes Rd
Portland, Oregon 97225
Portland, Oregon 97225
(503) 216-1234
Principal Investigator: Robert Hodson, MD
Providence St. Vincent Medical Center Providence St. Vincent is renowned for its many centers of...
Click here to add this to my saved trials
Raleigh, North Carolina 27607
Principal Investigator: R. Lee Jobe, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
2315 Stockton Blvd.
Sacramento, California 95817
Sacramento, California 95817
(916) 734-2011
Principal Investigator: Jeffrey Southard, MD
University of California, Davis Medical Center UC Davis Medical Center serves a 65,000-square-mile area that...
Click here to add this to my saved trials
1 Barnes Jewish Hospital Plaza
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
Principal Investigator: John Lasala, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Ming Zhang, MD
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
Seattle, Washington 98195
(206) 598-3300
Principal Investigator: Creighton Don, MD
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
Click here to add this to my saved trials
Springfield, Illinois 62701
Principal Investigator: Gregory Mishkel, MD
Click here to add this to my saved trials
300 Pasteur Dr
Stanford, California 94305
Stanford, California 94305
(650) 723-4000
Principal Investigator: Alan Yeung, MD
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
Click here to add this to my saved trials
110 Irving St NW
Washington, District of Columbia 20010
Washington, District of Columbia 20010
(202) 877-7000
Principal Investigator: Ron Waksman, MD
Washington Hosp Ctr MedStar Washington Hospital Center is a not-for-profit, 926-bed, major teaching and research...
Click here to add this to my saved trials
Winston-Salem, North Carolina 26157
Principal Investigator: David Zhao, MD
Click here to add this to my saved trials